AstraZeneca PLC American Depositary Shares (AZN)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Drugmaker AstraZeneca forecasts sales and profit growth in 2026
AstraZeneca on Tuesday forecast profit and sales growth in 2026, betting on demand for its cancer and cardiovascular treatments while the drugmaker pursues massive expansion in the U.S. and China.
Will These 5 Drug Bigwigs Surpass Q4 Earnings Forecasts?
Let's look at five pharma and biotech companies, AZN, INCY, GILD, VRTX and MRNA, which are scheduled to release their fourth-quarter 2025 results this week.
Countdown to Astrazeneca (AZN) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS
Besides Wall Street's top-and-bottom-line estimates for Astrazeneca (AZN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2025.
AstraZeneca to Report Q4 Earnings: What's in Store for the Stock?
AZN gears up for Q4 results as cancer, diabetes and rare disease drugs drive sales expectations ahead of the Feb. 10 earnings report.
FDA Rejects AZN's Saphnelo SubQ Formulation, Priority Tag to Datroway
AstraZeneca wins FDA priority review for Datroway in triple-negative breast cancer, while Saphnelo SC receives a complete response letter.
Why Astrazeneca (AZN) Dipped More Than Broader Market Today
The latest trading day saw Astrazeneca (AZN) settling at $184.32, representing a -2.17% change from its previous close.
AstraZeneca's Initial Application for Lupus Injection Turned Down by FDA
The company is working with the U.S. regulator to move forward with an updated application, adding a decision is expected in the first half of 2026.
AZN Obesity Pipeline to Get a Boost From Deal With China's CSPC
AstraZeneca deepens its obesity push with an eight-program deal with China's CSPC, securing rights to a once-monthly injectable weight-management pipeline.
AstraZeneca begins trading directly on the NYSE
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) shares start trading directly on the New York Stock Exchange today, establishing a harmonised global listing along with London and Stockholm. Up to now, US investors could buy the drugmaker's equity via American Depositary Receipts (ADRs), which were listed on the Nasdaq, with each two representing one of the company's ordinary shares.
AstraZeneca is listing in New York, as Big Pharma balances the huge U.S. market with China's tempting innovation
AstraZeneca has announced it's investing $15 billions in China, and said it is partnering with a Chinese biotech to develop weight-loss drugs. The developments come at a critical time for the pharma industry as companies are increasingly looking east for innovation to replace revenue from blockbuster medicines going off patent in the next few years.
AstraZeneca obesity tie-up with CSPC seen as shrewd move
AstraZeneca PLC's (LSE:AZN, NASDAQ:AZN) licensing deal on Friday signals a plausible effort by the FTSE 100 group to grab a piece of a booming market for obesity treatments, analysts said, with still plenty to go far despite the market currently being dominated by rivals Novo Nordisk and Eli Lilly. The pharmaceutical group agreed to pay China's CSPC Pharmaceuticals $1.2 billion upfront, with a further $3.5 billion in milestone payments, for rights to eight early-stage weight management and diabetes programmes, including a clinical-ready injectable drug expected to begin trials soon.
AstraZeneca Strikes Multibillion-Dollar Obesity Deal With China's CSPC
The agreement to gain rights outside of China to a portfolio of experimental obesity and diabetes drugs could be valued at billions of dollars.
